
CHAMPIONING MEDICALLY INTEGRATED ONCOLOGY:
Celebrating
a Decade of Impact
2025 NCODA INTERNATIONAL
FALL SUMMIT

1


Reimagining CAR-T:
The Outpatient Evolution
Rebecca Gonzalez,
PharmD, BCOP, FASTCT
Blood and Marrow Transplant/Cellular
Immunotherapy Clinical Specialist
2025 NCODA INTERNATIONAL
FALL SUMMIT
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

2


OBJECTIVES
2025 NCODA INTERNATIONAL
FALL SUMMIT
1. Identify key patient, caregiver, and product-related aspects to ensure a safe outpatient Chimeric Antigen Receptor Therapy (CAR-T) journey
2. Discuss toxicity mitigation strategies, including monitoring, management protocols, and risk-adapted approaches for outpatient CAR-T therapy
3. Outline the multidisciplinary team roles, infrastructure, workflow, and safety protocols essential for outpatient CAR-T program implementation
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

3

DISCLOSURES

2025 NCODA INTERNATIONAL FALL SUMMIT

The following relevant financial relationships from the past 24 months have been identified and disclosed for the following planners of this CE activity:

- Stephanie Parker, PharmD
  - Aveo, Partner Therapeutics, Nuvation Bio

There are no relevant conflicts of interest to disclose for this presentation for the following speakers and planners of this CE activity:

- Rebecca Gonzalez, PharmD, BCOP, FASTCT
- Tahsin Imam, PharmD

This activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States.

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

4

Current Treatment Landscape and Future Evolution of Chimeric Antigen Receptor Therapy (CAR-T)

- CAR-T is considered a major breakthrough in hematology Tx with effective and durable responses
  - Historically, focused on chemotherapy within community centers
    - Referral to certified centers for CAR-T delivery
- Success of CAR-T in early setting and in trial-ineligible patients highlights the critical need for broader access
- Shift in demand for OP CAR-T similar to aHCT
  - Driven by resource constraints and better understanding and management of toxicities
  - Comparable efficacy with reduced cost/tx burden

CIBMTR 2024 Summary Analysis: Current use of Cellular Therapy and CAR-T Infusions by Indication in the US annually



Haslam A, et al. *Blood Adv.* 2024;8(4):1032-1036. Spellman SR, et al. *Transplant Cell Ther.* 2025 Aug;31(8):505-532., Bhaskar ST, et al. *Clin Hematol Int.* 2024;6(4):85-99., Alaina M, et al. *Future Oncol.* 2025;21(10):1137-1144., Hansen DK, et al. *Cancers.* 2023;15: 5746., Mikhael J, et al. *JCO Oncol Pract* 2022; **18**, 600-607.

Tx: treatment, MM: multiple myeloma, OP: outpatient, CIBMTR: Center for International Blood and Marrow Transplant Research, US: United States, aHCT: autologous hematopoietic cell transplant

5

US FDA Approvals of CAR T-cell Therapy

Lymphoma (CD-19 Targeted)

- 2017 — **Axicabtagene ciloleucel (axi-cel)**
  - Initial Approval: 3rd line LBCL
  - Subsequent Approval: 2nd line LBCL, 3rd line FL
- 2020 — **Tisagenlecleucel (tisa-cel)**
  - Initial Approval: 3rd line LBCL
  - Subsequent Approval: 3rd line FL
- 2021 — **Brexucabtagene autoleucel (brexu-cel)**
  - Initial Approval: as early as 2nd line for MCL
- 2021 — **Lisocabtagene maraleucel (liso-cel)**
  - Intial Approval: 3rd line LBCL
  - Subsequent Approval: 2nd line LBCL, 3rd line for CLL/SLL, 3rd line FL, 3rd line MCL

Leukemia (CD-19 Targeted)

- 2017 — **Tisa-cel**
  - Initial Approval: R/R B-ALL: peds/AYA; up to 25yo
- 2021 — **Brexu-cel**
  - Subsequent Approval: R/R B-ALL: adults; 18yo+
- 2024 — **Obecabtagene autoleucel (obe-cel)**
  - Initial Approval: R/R B-ALL: adults; 18yo+

Myeloma (BCMA Targeted*)

- 2021 — **Idecabtagene vicleucel (ide-cel)**
  - Initial Approval: 4th line MM
  - Subsequent Approval: 3rd line MM
- 2022 — **Ciltacabtagene autoleucel (cilta-cel)**
  - Initial Approval: 4th line in MM
  - Subsequent Approval: 2nd line MM
- 2026 — **Arlocabtagene autoleucel (arlo-cel)**
  - *Initial PDUFA date February 8, 2026*
  - *Note: GPRC5D-targeted CAR-T Product**

LBCL: large b-cell lymphoma, FL: follicular lymphoma, MCL: mantle cell lymphoma, CLL: chronic lymphocytic lymphoma, SLL: Small Lymphocytic Lymphoma, ALL: acute lymphocytic leukemia, R/R: relapsed/refractory, yo: years old, PDUFA: prescription Drug User Fee Act, GPRC5D: G-protein coupled receptor family C group 5 member D

Neelapu SS, et al. *N Engl J Med.* 2017;377(26):2531-2544., Maude SL, et al. *N Engl J Med.* 2018;378:439-448., Shah BD, et al. *Lancet.* 2021; 398: 491-502., Roddie C, et al. *N Engl J Med.* 2024;391(23):2219-2230., Jacobson CA, et al. *Lancet Oncol.* 2022;23(1), Foster NH, et al. *Nat Med.* 2022;28(2)., Abramson JS, et al. *Lancet.* 2020;396(10254):839-852., Kamiar M, et al. *Lancet Oncol.* 2022;23(1):91-103., Munshi NC, et al. *N Engl J Med.* 2021;384(8):705-716., Berdeja JG, et al. *Lancet.* 2021;398(10314):314-324., Rasko JEJ, et al. *Blood.* 2024;144(suppl 1):922. Rakesh Popat, et al. JCO. 2025;43:16_suppl, TPS7564-TPS7564., Rodriguez-Otero P, et al. *N Engl J Med.* 2023;388(11):1002-1014., San-Miguel J, et al. *N Engl J Med.* 2023;389(4)., Bal S, et al. *Blood.* 2024;144(suppl 1):922. Rakesh Popat, et al. JCO. 2025;43:16_suppl, TPS7564-TPS7564.

2025 NCODA INTERNATIONAL FALL SUMMIT

6


CAR-T Journey: Collection to Manufacturing
Leukapheresis
Collect patient's own WBC's
Shipped to manufacturer
Manufacturing (Vein to Vein ~4-6 weeks)
Isolate/activate T-cells
Genetically engineered T-cells with CAR gene
Insert gene for CAR
CAR-T cell
Antigen binding domain (e.g., CD19, BCMA)
Costimulatory domain (CD28 or 4-1BB)
Signaling domain (CD3ζ)
Grow and expansion of CAR-T product
Consultation and work-up
CTNC, Provider, APP
Review labs/ VOTs
Enroll patient, sign informed consent, education
Leukapheresis
Vein assessment +/- transfuse to collection parameters
Apheresis teaching
Collect cells, package and ship product
Bridging chemo/"Wash out" period
Bridge to CART: palliate symptoms, debulk tumor, etc.
Preserve functional status to safely administer cells
May include chemotherapy, steroids, +/- XRT
WBC: white blood count, CTNC: Cellular Therapy Nurse Coordinator, APP: Advanced Practice Provider, VOTs: vital organ testing, XRT: radiation therapy
2025 NCODA INTERNATIONAL FALL SUMMIT

7


CAR-T Journey: Lymphodepleting Chemotherapy (LD) to Adverse Events
LD Chemotherapy
Days -5, -4, -3
Cell Infusion
Infuse patient with engineered CAR T-cells
CAR-T Expansion/Persistence
On Target-On Tumor/On Target-Off Tumor Effects
Toxicity Spectrum
CRS
ICANS
IEC-HS
Infections
Bacterial, Fungal, Viral
ICAHT
Neutropenia, Thrombocytopenia, Anemia
Day 7
Day 14
Day 21
Day 28
LD Chemotherapy
Goal: deplete lymphocytes/suppressive cells to foster in vivo proliferation
Composed of 3-5 days of combined agents (e.g., FluCy)
Side effect management: pancytopenia, GI toxicity, fatigue
Cell Administration
Clearance: central line, vitals/labs stable, no active infection
Product verification and wallet card provided to patient
Infusion reaction monitoring (cryopreserved)
Premeds & pre/post hydration
Side-effect monitoring
CRS/ICANS/Other
NF/infection work-up
Count Recovery/Lab abnormalities
Need for transfusions, growth factor support, IVIG
FluCy: fludarabine, cyclophosphamide, CRS: Cytokine release syndrome, ICANS: Immune effector cell-associated neurotoxicity syndrome, IEC-HS: Immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome, ICAHT: Immune Effector Cell-Associated Hematotoxicity, GI: gastrointestinal, NF: neutropenic fever, IVIG: Intravenous immunoglobulin
2025 NCODA INTERNATIONAL FALL SUMMIT

8


Perceived CAR-T Barriers Among US-based Large Academic and Community Practice
Barriers
Potential Solutions
CAR-T Tx Process/ Logistics
Restriction to specialized center
Slow intake process
Requirement for patients to remain in specified radius of center
Lost wages for caregivers
Bridging therapy due to vein-to-vein time
CAR-T Tx Process/ Logistics
Authorization for both IP/OP setting administration
Some OP components or reduced timing for IP stay
Remote monitoring
Collaborative follow-up with local oncologist post-CAR-T
Manufacturing
Limited manufacturing slots
Manufacture failures
Manufacturing
In-house manufacturing
Use of OOS products
IP: inpatient, OP: outpatient, OOS: out of specification
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

9

Perceived CAR-T Barriers Among US-based Large Academic and Community Practice

Barriers		Potential Solutions	
Reimbursement/ Financial burden	▪ **Health plan restrictions/denials for coverage of adoptive cell therapies** ▪ Slow approval process by payers ▪ Patient deterioration (in-eligible)	**Reimbursement /Financial burden**	▪ Streamline mechanisms for equitable reimbursement ▪ **Utilize manufacturer-provided resources for patient support, insurance coverage and benefit verification**

Alsabeh R, et al. *Transplant Cell Ther.* 2024;30(2S): S370S396., Gajra A, et al. *Immunotherapy.* 2020 Jul;12(10):725-732.

10

Advocacy for Safe and Equitable Access: Mission Accomplished June 26, 2025

- ASTCT 80/20 Taskforce (now subcommittee) was developed in 2020
  - Standardize/streamline requirements for onboarding [illegible] cellular the[illegible]
- Mission: prov[illegible] use of CAR-T[illegible]
  - Collaborativ[illegible] burden red[illegible]

ASTCT 80/20 effectively advocated to streamline

ASTCT 80/20 consensus on key cell therapy community efforts to [illegible]afe delivery of CAR-T

[illegible]s responsible for standards of care [illegible]e CAR-T toxicities

[illegible]es provide CAR-T safety education

[illegible]ted to a central repository, such as [illegible]m to each manufacturer

[illegible]l accreditation groups, such as FACT, [illegible]most oversight, not manufacturers

[illegible]ess experience have different needs for [illegible] oversight

FDA NEWS RELEASE

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies

Agency determines the safety and effectiveness of these immunotherapies can be assured without a REMS

Locke F, et al. *Transplant Cellular Ther.* 2025;31:349.e1 349.e12. Image available under creative commons CC BY-NC-ND license., FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies. Accessed August 15, 2025, from: https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor.

11

Financial Considerations for OP CAR-T: Creating a Sustainable and Patient-centric Approach

Reimbursement varies based upon public vs. private insurance and administration location

- High cost of CAR-T can be exacerbated by reimbursement restrictions
  - Ensure single case/contractual agreements include IP and OP sites of care
  - OP reimbursement*: average $ for CAR-T + ~ 6%
    - Medicare uses OP prospective payor system (OPPS):
      - PPS-non-exempt: 99% of other centers (fixed rate per patient) vs. PPS-exempt: 11 Cancer Centers (“reasonable cost payment”)
  - IP reimbursement MS-DRG base payment
  - Medicare copays capped
  - Medicaid coverage varies (product/state-specific)

Ensure thorough EMR documents for labeling criteria

*Product price increase may occur and need to be vigilantly monitored for updates
MS-DRG: Medicare Severity Diagnosis-Related Group

Jagannath S, et al. *Oncol Ther.* 2023 Jun;11(2):263-275., American Society for Transplantation and Cellular Therapy. ASTCT CAR-T therapy coding and billing guide. Updated January 2025. Accessed August 15, 2025. https://www.astct.org/Portals/0/ASTCT_14022025-25_BillingandCoding_CT_FINAL.pdf., Akins M, et al. *Future Oncol.* 2025;21(10):1131-1144.

12

Financial Considerations for OP CAR-T: Creating a Sustainable and Patient-centric Approach

Even with insurance there is significant financial burden

- Medical costs, lost wages (patient/caregiver) and lodging/transportation
- Ensure access to general financial support for these out-of-pocket expenses
  - ➢Local lodging programs or grants

Shifting CAR-T to the OP setting may improve patient experience, optimize HCRU, and decrease costs:

- Decreased hospital bed usage
- Shorter hospital stays
- Lower costs (patent and institution)
- Improved patients QoL

Jagannath S, et al. *Oncol Ther*. 2023 Jun;11(2):263-275., American Society for Transplantation and Cellular Therapy. ASTCT CAR-T therapy coding and billing guide. Updated January 2025. Accessed August 15, 2025. https://www.astct.org/Portals/0/ASTCT_1492250-25_BillingandCoding_Q1_FINAL.pdf , Alaina M, et al. *Future Oncol*. 2025;21(10):1137-1144.

HCRU: Healthcare resource utilization , QoL: quality of life, EMR: electronic medical record

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

13

OP Administration Can Reduce Healthcare and Patient Costs While Maintaining Suitable Benefit-Risk Profile

Jagannath S, et al. Cilta-cel Component Cost of CAR-T: Average Total Costs Per Patient Based on 3 Phasesψ



ψPopulation based on CARTITUDE-1: Exploring 3 Phases of Cost Components: pre-infusion, peri-infusion, post-infusion

Palomba ML, et al. Liso-cel Cost of Care: IP vs. OP

Retrospective review of TRANSCEND 001 and OUTREACH trials (N = 303)

62% infused OP required admission

- 21% within 72 hours
- Admission LOS, median (range)
- 15 (0-88) IP vs. 4 (0-77) OP

38% of OP never required admit within 6-months

Estimated 6-month post-CAR-T HCRU savings

- $89,535 IP vs. $36,702 OP

Hansen, et al. Direct Costs of pooled TRANSCEND 001, OUTREACH, TRANSFORM and PILOT (liso-cel) Clinical Trials with OP and IP data

6-month post-infusion cost 2-4 x higher
•2-3x longer LOS IP

Cost reduction driven by reduced hospitalization costs

Jagannath S, et al. *Oncol Ther*. 2023 Jun;11(2):263-275., Palomba ML, et al. *Leukemia Lymphoma*. 2021;9:2169-76., Hansen DK, et al. *Cancers (Basel)*. 2023. Doc 7:15(24):5746.

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

14

Considerations for Successful Implementation of Outpatient CAR-T

2025 NCODA INTERNATIONAL FALL SUMMIT

15


QUESTION ARS #1
2025 NCODA INTERNATIONAL FALL SUMMIT
You are currently planning on developing outpatient CAR-T at your institution. During a strategic planning meeting you were asked what components of CAR-T can be administered in outpatient care setting?
a. Lymphodepleting chemotherapy (Day -5 to Day -3)
b. Cells infusion (D0)
c. Close monitoring post-cell infusion for certain eligible products
d. All of the above
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

16


Suitability Criteria for OP Administration of CAR-T
Key: Purposeful Selection
Patient
- Limited comorbidities with good PS
- Reliable 24-hour caregiver support
- Relatively stable disease burden, low risk of severe CRS/ICANS
Product
- Predictable timeline of toxicities
- Gradual onset of potentially severe toxicities
PS: performance status

17


Overall Patient/Product Considerations for CAR-T Eligibility*
Indications and limitations
Consider antigen loss (e.g., CD19 for CD19-directed CAR-T)
Insurance coverage/preference of product
How time sensitive/urgent is treatment?
Is the patient at high risk of toxicity?
High tumor burden/need for bridging therapy
Multiple comorbidities
Life expectancy > 6 weeks
Adequate organ function
ECOG PS: 0-2
Ability to tolerate LD chemo
Ability to tolerate CAR-T cell–related toxicities
No active/ uncontrolled infections
Caregiver support pre, during, and post CAR-T
Housing/financial support
*Criteria for eligibility may differ from site by site
ECOG PS: Eastern Cooperative Oncology Group performance score
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

18

Do's and Don'ts of Patient Selection for OP Administration

Ideal

- No bulky disease or large tumor burden (risk of severe CRS/ICANS)
- No organ dysfunction/significant comorbidities
- Good health literacy and compliance/adherence
- Reliable caregiver and transportation

Not-ideal

- Dialysis-dependent
- Progressive disease symptoms (new onset AKI, TLS, etc.)
- Poor performance status or mobility (preventing tolerability of CRS)
- High psychosocial risk

OP CAR-T should be planned & discussed with patient by primary provider and CAR-T team at re-evaluation and outlined in EMR

TLS: tumor lysis syndrome, AKI: acute kidney injury

Oluwole OO, et al. *Transplant Cellular Ther.* 2024. Feb;30(2):131–142., Akins M, et al. *Future Oncol.* 2025;21(10):1137-1144.

19

Critical Caregiver Factors Essential for OP CAR-T Administration

- Reliable transportation to/from facility
  - Apheresis/line placement until return to home
- Local lodging to center post-infusion
  - Within designated distance (~30-60 minutes)
- Access to a committed 24/7 caregiver
  - As early as LD therapy
  - Understanding of roles/responsibility to track symptoms and manage medications



Akins M, et al. *Future Oncol.* 2025;21(10):1137-1144., Oluwole OO, et al. *Transplant Cellular Ther.* 2024. Feb;30(2):131–142., Hansen DKD, et al. Front Immunol. 2024 Feb 21–24;15:1405452.

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

20

CAR-T Limitations: Rebalancing the Scale with OP Administration



- Historically, CAR-T was administrated in IP setting driven by serious AE's (CRS, ICANS, etc.) and need for close monitoring
  - Better understanding and predictability of the clinical course increased OP interest
    - Most experience is with 4-1BB products given toxicity profile
      - CD28 products possible with additional support and vigilance
- With appropriate infrastructure planning OP is feasible leading to several patient and institutional advantages:
  - More cost favorable without compromise in clinical outcomes
  - Associated with shorter hospitalization duration
  - Increase access and reduced patient/caregiver burden

AE's: Adverse events

Alexander M, et al. *Transplant Cell Ther.* 2021;27:558, Gatwood KS, et al. *EJPharm.* 2021;3(Suppl 1):54-6 0., Oluwole OO, et al. *Transplant Cellular Ther.* 2024. Feb;30(2):131–142.

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

21



22



CD28	4-1BB
Member of the immunoglobulin (Ig) family	Member of the TNF receptor superfamily
• Expands **preferentially effector-like T-cells** rapidly (limited CAR persistence)	• **Expands memory-like T-cells** (slow activation but enhanced persistence)

ScFV: short-chain variable fragment, TM: transmembrane

23



Toxicity Spectrum	Patient	Disease	Product/Tx Related	Additional Considerations
CRS*	Comorbidities +/- age, infections, **elevated inflammatory markers,** thrombocytopenia	**Tumor burden**, CNS involvement	Higher dose of CART-cells, **Co-stimulatory Domain [CD28 > 41BB CARs,** Flu-containing/ intensity of LD	**Onset/Duration variable and product specific**
ICANS*	CRS, **elevated inflammatory markers,** younger age, pre-existing neuro conditions, thrombocytopenia	**Tumor burden**, +/- CNS Involvement		ICANS often preceded by CRS
ICAHT + hypogam.**	**Elevated inflammatory markers,** older age, high baseline BM blasts	Refractory, poorly controlled disease, **Tumor burden**	Multiple prior LOT, intensity of LD	Multifactorial: poor patient condition, tumor burden, pe-treatment LD ***Consider CAR-HEMATOTOX**
Infections**	Age/comorbidities, Hx of CRS, Existing cytopenia's, prior frequent infections, hypogam	Refractory, poorly controlled disease	High-dose & long-duration steroids, other immunosuppressive treatments	Prior infections, biological age vs. chronological age

*Modified EASIX score=(LDH×CRP)/Platelets is associated with severe CRS and ICANS
** CAR-HEMATOTOX score: Score ≥2 pts are at risk for severe prolonged neutropenia and infections

BM: bone marrow, Hx: history, LOT: lines of therapy, Hypogam: hypogammaglobulinemia, CNS: central nervous system, CRP: c-reactive protein, LDH: lactate dehydrogenase

24

Trustworthy Terrain: Navigating Product Choices with Predictable Safety

Best product selection for OP administration is dependent on main 2 factors:

1. Attributes of **toxicity onset** and **incidence of severe CRS/ICANS** events
   - Delayed onset of toxicities is ideal
     - Potential for OP administration from LD to onset of toxicity warranting IP stay
     - Hospitalization only for toxicity management
   - Low incidences of severe Gr. 2+ CRS/ICANS
     - Management of Gr. 1 CRS in OP setting feasible
2. Products with rapid onset of toxicities may be feasible for early discharge options

Example OP CAR-T RWE Studies

Disease State	Product	OP Infusion	Time to Admit (days)	Admit LOS Median (days)
MM, ALL, LBCL	Ide-cel, Tisa-cel, Liso-cel	80% (n=32/40)	2 (pre-emptive D0 approach, n=21)	8-14 vs. 19 IP only
LBCL	Tisa-cel	59% (n=93/157)	2.5 (45%OP required admit)	5 vs.13 IP only
ALL, LBCL	Axi-cel, Tisa-cel, Brexu-cel	96% (n=47/52)	2-4 (82% OP required admit)	7-10
MM	Cilta-cel	62.8% (n=27/43)	NR (92.6% OP required admit)	4 vs. 11 IP only

Gr: grade, LOS: length of stay RWE: real world experiences, NR: not reported

Chavda OO, et al. *Transplant Cellular Ther.* 2024. Feb;30(2):131–142., Hansen DKD, et al. *Front Immunol.* 2024. Feb 21–24;15:1405452., McGann M, et al. *Transplant Cell Ther.* 2022 Sep;28(9):583-585, Ahmed N, et al. *Transpl Cell Ther.* 2023 Jul;29(7):e448.1–e449.7. , Ly A, et al. *Br J Haematol.* 2023;203(4):689-692., Waqar, Syed Hamza Bin, et al. *Transpl Cell Ther.* 2024. 30(2):S388.

25

CRS and ICANS: Incidence, Onset and Duration of FDA Approved CAR T-Cell Products

LBCL Products

	Axi-cel DLBCL ZUMA-1	Axi-cel FL ZUMA-5	Brexu-cel MCL ZUMA-2	Tisa-cel DLBCL JULIET	Liso-Cel DLBCL TRANSCEND	Liso-Cel FL TRANSCEND FL
Gr. 3+ CRS	13%	**8%**	15%	22%	**2%**	**1%**
Median onset/ duration CRS	**2 days/** 8 days	**4 days/** 6 days	2 days/ 11 days	3 days/ 7 days	**6 days/** 5 days	**6 days/** 3 days
Gr. 3+ ICANS	28%	21%	31%	12%	10%	2%
Median onset/ duration ICANS	5 days/17 days	**6 days/** 16 days	7 days/ 12 days	6 days/ 14 days	**9 days/** 11 days	**8.5 days/** 3.5 days

Delayed Onset (~ Day 4+) or **low Gr. 3+ events**: Potential for OP administration and IP for toxicity management

Early Onset (~ Days 1-3): Potential for early discharge from IP post-toxicity

ALL Products

	Brexu-cel B-ALL ZUMA-3	Tisa-cel B-ALL ELIANA	Obe-cel B-ALL FELIX
Gr. 3+ CRS	24%	46%	3%
Median onset/ duration CRS	5 days/ 7.5 days	3 days/ 8 days	**8 days/** 5 days
Gr. 3+ ICANS	25%	13%	7%
Median onset/ Duration ICANS	9 days/ 7 days	<8 weeks/ 10 days	**12 days/** 8 days

MM Products

	Ide-cel MM KarMMa	Cilta-Cel MM CARTITUDE-1
Gr. 3+ CRS	5%	4%
Median onset/ duration CRS	1 day/ 5 days	**7 days/** 4 days
Gr. 3+ ICANS	3%	2%
Median onset/ Duration ICANS	2 days/ 3 days	**8 days/** 4 days

Neelapu SS, et al. *N Engl J Med.* 2017;377(26):2531-2544., Maude SL, et al. *N Engl J Med.* 2018;378:439-448., Shah BD, et al. *Lancet.* 2021; 398: 491-502 , Roddie C, et al. *N Engl J Med.* 2024;12;391(23):2219-2230., Jacobson CA, et al. *Lancet Oncol* 2022;23(1), Fowler NH, et al. *Nat Med.* 2022;28(2)., Abramson JS, et al. *Lancet.* 2020;396(10254):839-852 , Kamdar M, et al. *Lancet.* 2022;399(10343)., Munshi NC, et al. *N Engl J Med.* 2021;384(8):705-716., Wang M, et al. *N Engl J Med.* 2020;382(14):1331-1342., Bendaji JC, et al. *Lancet.* 2021;398(10297)., Rodriguez-Otero P, et al. *N Engl J Med.* 2023;388(11):1002-1014., San-Miguel J, et al. *N Engl J Med.* 2023;389(4)., Bal S, et al. *Blood.* 2024;144(suppl 1):922.

26

Institutional Infrastructure Needs for OP Administration: Dedicated Space or Bed Availability



27


Toxicity Strategies for Outpatient CAR-T Administration
2025 NCODA INTERNATIONAL FALL SUMMIT

28


Considerations for CAR-T Toxicity Monitoring in OP Setting
Utilize consult services at baseline to identify existing concerns
Infectious disease, social work, neurology, etc.
Create standardized EMR form for daily assessment (CRS/ICANS)
Documentation is vital for effective and timely interventions
Develop institutional criteria/monitoring protocols that are product/disease specific
Eligibility for OP CAR-T vs. early transition to OP
Create transition of care email group with all stakeholders
Standardize monitoring requirements during OP CAR-T visits and at home
CRS Toxicity
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

29


Protocol Considerations for Prompt Escalation of Care
Determine institutional guidance of expected AE's that can be managed in OP setting
Low-grade CRS, cytopenia's, neutropenic fever, etc.
Develop required IP treatment/monitoring Criteria
Any Gr. 2 or higher CRS or any ICANS should trigger admission (obs status)
DO NOT PASS GO
INPATIENT STAY TRIGGERED
Streamline intake process for IP admission when needed
Transparency of clinical status: EMR handoff tools, sign-outs, etc.
Electronic notification tools including all stakeholders
Chat/email groups for timely notification
Obs: observation
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

30

ASTCT Consensus CRS Grading and Manifestations

Parameter	Grade 1	Grade 2	Grade 3	Grade 4
Fever*	Temp ≥ 38 °C (100.4 °F)			
With either:				
Hypotension	None	Not requiring vasopressors	One vasopressor +/- vasopressin	Multiple vasopressors (excluding vasopressin)
And/or				
Hypoxia	None	Low-flow nasal cannula or blow-by	High-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask	Positive pressure (CPAP, BiPAP, intubation, and mechanical ventilation)

*Fever defined as temperature 38°C not attributable to any other cause.
- CRS patients who receive antipyretic or anti-cytokine therapy (tocilizumab, steroids, others) *fever is no longer required* to grade subsequent CRS severity
  - CRS grading driven by hypotension and/or hypoxia.

Other: Hepatic, renal, cardiovascular, pulmonary, GI, musculoskeletal, neurologic, hematologic
Note: Organ toxicities associated with CRS can be graded per CTCAE v.5 but doesn't influence CRS grading

Can progress to life-threatening vasodilatory shock, capillary leak, hypoxia and multiorgan failure

Low-flow nasal cannula: oxygen delivered at ≤6 L/minute
High-flow nasal cannula: oxygen delivered at >6 L/minute

Lee DW et al. *Biol Blood Marrow Transplant.* 2019;25(4):625-38

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

31

ASTCT Consensus ICANS Grading and Manifestations

ICE Score	
Task	**Points**
Orientation: orientation to year, month, city, hospital:	4
Naming: ability to name 3 objects	3
Following commands: ability to follow simple commands (e.g., show me the TV remote)	1
Writing: ability to write a standard sentence	1
Attention: ability to count backwards from 100 by 10	1

Neurotoxicity Domain	Grade 1	Grade 2	Grade 3	Grade 4
ICE score*	7-9	3-6	0-2	0 (patient is unarousable and unable to perform ICE)
Level of consciousness%	Awakens spontaneously	Awakens to voice	Awakens tactile stimulus only	Unarousable or requires vigorous or repetitive stimuli to arouse; Stupor or coma
Seizure	N/A		Any clinical seizure or nonconvulsive seizures on EEG that resolve with intervention	Life-threatening prolonged seizure (>5 min) or repetitive clinical or electrical seizures without return to baseline
Motor findings	N/A			Deep focal motor weakness (hemiparesis or paraparesis)
Elevated ICP/cerebral edema	N/A		Focal/local edema on neuroimaging	Diffuse cerebral edema on neuroimaging; or cranial nerve palsy; or papilledema; or Cushing's triad

*A patient with an ICE score of 0 may be classified as grade 3 ICANS if awake with global aphasia, but patient with an ICE of 0 may be classified as grade 4 ICANS if unarousable
%Depressed level of consciousness should be attributable to no other cause (e.g., no sedating medication)

ICE score: Immune Effector Cell-Associated Encephalopathy
ICP: intracranial pressure, ICE: Immune effector cell associated Encephalopathy

Lee DW et al. *Biol Blood Marrow Transplant.* 2019;25(4):625-38

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

32

Principles of Toxicity Management: No Universal Guideline for Toxicity Management

Protocols vary by institution
- Rates of CRS/ICANS vary among products, disease, and patient characteristics
- Appropriate screening per institutional standards
- Baseline labs: CRP, ferritin, CBC/CMP, coagulopathy, and TLS labs

CRS:
Immune activation correlates with CAR expansion and elevations inflammatory markers and cytokines
- Symptomatic management of mild CRS is universal and relies on supportive care measures
- **Tocilizumab: 1st line treatment for CRS**
- Steroids typically reserved for tocilizumab-refractory CRS
- Alternative anti-cytokine therapy may be needed in refractory setting

ICANS
- Tocilizumab not effective
  - Does not penetrate CSF
  - May increase IL-6 levels and worsen ICANS
- **Corticosteroids: 1st line treatment**

CBC: complete blood count, CMP: comprehensive metabolic panel,
CSF: cerebrospinal fluid, IL: interleukin

Santomasso BD, et al. *Cancer Discov.* 2018 Aug;8(8):958-971., Hay KA, et al. *Blood.* 2017;23:130(21):2295-2306., Maus MV, et al. *J Immunother Cancer.* 2020;8(2):e001511.

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

33


Toxicity Algorithms and Interventions
CRS onset usually within 1st week after CAR T-cell therapy (peaks within 1-2 weeks)
• #1 is to rule out other etiologies: infections vs. comorbidity flare vs. drug induced
ICANS can be biphasic and occur during CRS and/or present as late or delayed events
• Patients with ICANS should receive AED (if not given prophylactically) + appropriate CNS imaging/EEG monitoring
Gr. | CRS | ICANS | CRS + ICANS
1 | Scheduled APAP x 24hrs ± Toci*≠ | Supportive care (± dex)* | Supportive care (± Toci)*
2 | Toci ± Dex | Steroids (dex) | Toci + dex
3 | Toci + steroid +/- ICU transfer¥ | Steroids (dex or MP); Consider ICU transfer | Toci + dex or MP
4 | Toci + steroid¥ + ICU transfer | High-dose MP until Gr 1; ICU/critical care∞ | Toci + High-dose MP; ICU/critical care∞
Steroid dosing: dexamethasone (10-20mg), HD steroids: MP (500-1000mg)
Special Considerations:
• * Toci for frail/elderly and those with persistent fever > 72hrs
• ≠ Toci (+/- dex) for high-risk for progression to severe toxicities (dz. Burden, CD28 product, age/comorbidities)
• ¥ Consider refractory (MP IV with rapid taper) +/- other anti-cytokine therapy (e.g. anakinra or emapalumab)
• ∞ If life threatening, consider use of anakinra, emapalumab, cyclophosphamide or IT chemo
AED: antiepileptic drug, EEG: electroencephalogram, toci: tocilizumab, HD: high-dose, MP: methylprednisolone
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

34


Using Anti-cytokine Therapies Wisely
Description | Anti-IL-6 receptor mAb | Anti-IL-6 mAb | IL-1 receptor antagonist (IL-1Ra) | Anti-IFNγ mAb
MOA | Inhibits IL-6 mediated signaling by binding to IL-6R | Binds to soluble IL-6 inhibits both soluble & membrane bound IL-6R | Inhibits binding of IL-1 to its receptor | Binds free/ receptor-bound IFNγ, preventing JAK/STAT pathways signaling
Dose | < 30kg: 12 mg/kg vs. ≥30kg: 8mg/kg 800mg (max) q8hr, 4 doses total | 11mg/kg (max 1 dose/21 days) | Highly variable dosing ~100-200mg IV q6hr (IV q6= SQ q8) Consider max 7 days, (dosing up to 12 mg/kg/day) | 1mg/kg (1-dose) Note: use extrapolated from primary HLH indication
Admin | IV over 1hr | IV over 1hr | SQ or IV push over 1-3 minutes | IV over 1hr
Timescale for CRS/ICANS Onset and Relative Cytokine levels in Peripheral Blood
Cell infusion
IL-1β, 1Ra
GM-CSF
IL-6, IL-10, IFNγ, TNF
LD Chemo
IL-2, -7, -15
Days -5 to -3
0
+7
+14
+28
CRS
ICANS
MOA: mechanism of action, mAb: monoclonal antibody, r: receptor, IV: intravenous, SQ: subcutaneous, hr: hour, JAK/STAT: Janus kinase/signal transducer and activator of transcription, IL-1Ra: IL-1 receptor agonist (IL-1Ra), GCSF: granulocyte-macrophage colony-stimulating factor, IFNγ: interferon-γ, TNF: tumor necrosis factor, Admin: administration

35


Risk Adaptive Approaches To Mitigating Severe Toxicities
Risk-Adapted dosing: dosing based on disease burden and/or splitting cell doses
Obe-cel (CAT19-CD19) CAR-T
Holding of infusion if CRS/ICANS
• Real-time dose modifications
Adjusting affinity of binding domain for controlled antigen stimulation
Obe-cel CAT19 scFv
Future Directions:
• Controlled T-cell proliferation 4th and 5th generation CARs
• Logic-gating techniques
Prophylactic/Pre-emptive steroids or anti-cytokine therapy
Dexamethasone (corticosteroid)
Tocilizumab (IL-6R antagonist)
Siltuximab (IL-6 antagonist)
Anakinra (IL-1R antagonist)
Emapalumab (INFγ inhibitor)
Infliximab (TNFα inhibitor)

36

QUESTION ARS # 2

2025 NCODA INTERNATIONAL FALL SUMMIT

What prophylactic strategies can be used for high-risk CAR-T patients?

a. Tocilizumab + dexamethasone given Day -2
b. Dexamethasone given on Day 0, +1 and +2
c. There are no prophylaxis strategies at this time as it may impact CAR-T efficacy
d. Ibrutinib given on Day 0, +1 and +2

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

37

Early Intervention or Prophylactic Strategies to Mitigate CRS Toxicities without Compromising Efficacy

Prophylaxis
• Tocilizumab (Day 0 or Day +2)
• Dexamethasone 10 mg (Days 0, +1 and +2)
• Anakinra given on (Days 0, +1 and +2) or extend up to Day +7
• Anakinra given at 1st fever (or Day +2) up to minimum of 10 days

Pre-emptive Intervention (as early as Gr. 1)
• Dexamethasone
• Tocilizumab
• Anakinra
• Combination of Toci + Dex

Concurrent TKI in LBCL
Ibrutinib (BTK Inhibitor)
Itacitinib (JAK 1 Inhibitor)
Pirtobrutinib (BTK Inhibitor)**

***NCT06553872 in MCL treated with brexu-cel*

Oluwole OO, et al. *Br J Haematol.* 2021;194:690-700., Park JH, et al. *Nat Med.* 2023;29:1710-1717., Jain M. *Blood.* 2023, 141(20), 2430-2442., Strati. *Blood Adv.* 2023;7 (21): 6785–6789., Gardner RA, et al. *Blood.* 2019;134(24):2149-2158., Kadauke S, et al. *J Clin Oncol.* 2021 Mar 10;39(6):920-930., Cetrni PF, et al. *Front Immunol.* 2021;12:745320., Kadauke S, et al. *J Clin Oncol.* 2021;39(9):920-930., Topp MS, et al. *Br J Haematol.* 2021;195(3):389-395., Zurko JC, et al. *JAMA Oncol.* 2022;8(5):773-775., Gauthier J, et al. *Blood.* 2020;135(19):1650-1660., Prata M, et al. *Blood.* 2022;140(Suppl 1):10350-10351., Frigault, MJ, et al. *Blood.* 2020; 46(4):422–438., Mikos OR, et al. *Target Oncol.* 2025 Mar;20(2):217-234., Wanda WG, et al. *Blood.*2024;144 (Supplement 1):887.

38

Role of **CAR-HAEMATOTOX (HT) score** and Opportunity for Early Intervention/Supportive Care

Clinical utility of CAR-HT as a validated predictive tool

- Baseline patient characteristics used to evaluate for risk of CRS/ICANS + other complications
  - Risk stratification for severe infections, neutropenia and disease progression
  - The ALL HT omits ferritin for disease burden
- Online calculator for CAR-HT: https://www.european-mcl.net/home/scores-car-hematotox-286.html

Anticipate patient needs/allocating resource and guiding toxicity management

- Potential role in guiding escalation of anti-infective prophylaxis (+/- use early G-CSF use and stem cell boost)
- Role for prophylactic strategies (day 0-2) in high-risk patients
- Plan for early intervention strategies

CAR-HT Scoring			
Baseline features	**0 points**	**1 point**	**2 points**
Platelet count	>175K	75-175K	<75K
ANC	≥1200	<1200	-
Hemoglobin	≥9.0	<9.0	-
CRP	<3.0	≥3.0	-
Ferritin	<650	650-2000	>2000
Low risk (HT^{low}): 0-1 high risk		(HT^{high}): ≥2 (maximum 7)	

ALL-HT Scoring			
Baseline features	**0 points**	**1 point**	**2 points**
Platelet coun	> 175k	75-175k	< 75k
ANC	> 1200	< 1200	
Hgt	> 9	< 9	
CRf	< 3	> 3	
BM blasts	< 5%	5-25%	> 25%
Low risk: 0-3 points		High risk: ≥ 4 points	

k: thousand, G-CSF: Granulocyte Colony-Stimulating Factor

Rejeski K, et al. *Blood.* 2021;138(24):2499-513., Rejeski K, et al. *J Immunother Cancer.* 2022; 10(5): e004475., Rejeski K, et al. *Blood.* 2023;142(10):865-877.

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

39

General Monitoring Strategies for Acute Toxicity

Monitoring for CRS: onset usually within 1st week
- Close hemodynamic monitoring
- Monitor labs for organ dysfunction and inflammatory markers (ferritin/CRP)
- Initiate a full infectious workup and rapid implementation of anti-infective agents upon first signs of fever

Monitoring for ICANS: Manifestations can vary by product and occur up to Day +30
- Waxing and waning of symptoms
- ICE assessments at least twice daily (~14 days)

Tools to increase touchpoints
- Telehealth visits
- Post-visit phone calls
- Remote patient monitoring devices
  - Capacity to continually monitor temperature, pulse, respiratory rate and O_2 saturation
  - Can be utilized to decrease caregiver burden

SOC: standard of care, O: oxygen

Frey N, Porter D. *Biol Blood Marrow Transplant*. 2019;25(4):e123-e127., Rawstie S, et al. *Blood*.2023; 142 (Supplement 1): 1007, Lee, *Biol Blood Marrow Transplant*. 2019;25:625., Neelapu SS, et al. *Nat Rev Clin Oncol*. 2018; 15:47-62, Santomasso BD, et al. *Cancer Discov*. 2018;8:958–71., Oluwole OO, et al. *Transplant Cellular Ther*. 2024. Feb;30(2):131–142

40

General Monitoring/Supportive Care Strategies for Delayed Toxicity

- **Late onset toxicities are typically managed by treating facility or locally**
  - Supportive care strategies can be instrumental to reduce morbidity/mortality
- **B-Cell Aplasia/Hypogammaglobulinemia**
  - Check IgG levels monthly, then Q3-6mo
  - Administer IVIG if IgG levels < 400 mg/dL or < 600 mg/dL + recurrent infections
- **Hematologic toxicity with prolonged cytopenia's (ICAHT)**
  - Etiology multifactorial; Categorized as mild (Gr. 1), moderate (Gr. 2), severe (Gr. 3) and life-threatening (Gr. 4) categories
  - Managed with growth factor + other therapies
- **Late infections**
  - Ensure empiric antimicrobial are prescribed during neutropenia
    - ➢ As early as clearance day

ICAHT: Immune Effector Cell-Associated Hematotoxicity
*Product specific risk most associated with BCMA-directed CAR-T

Rejeski K, et al. *Blood*. 2023;142(10):865-877., Jain, et al. *Blood*. 2022;141:20: 2430-2442., Hill JA, et al. *Blood*. 2020; 20;136(8):925-935., Chakraborty R, et al. *Transplant Cell Ther*. 2021 Mar;27(3):222-22

41

Supportive Care Medications: Infection and Other Prophylaxis

TLS/Seizure	Antibacterial	Antiviral	Antifungal	
Allopurinol in high-risk patients • Higher BM burden, WBC and/or LDH (≥ 2000 U/L), etc. **Seizure prophy** Designated day pre-cells (e.g., D -1) • At time of neurologic toxicity	Recommended for patients with high risk of infections • Prophy may be considered once ANC is <500/µL	**VZV prophy in all patients** • LD up to 6+ months post-CAR-T and/or until CD4+ count is >0.2 × 10^9/L	**PJP prophy recommended** • LD or D+30 up to 6+ months post-CART and/or until CD4+ count is >0.2 × 10^9/L	**Antifungal prophy recommended** • Fluconazole/micafungin once ANC is <500/µL • Mold-active azole: high risk of IFI • High CAR-HT score, history of IFI, prolonged neutropenia, use of anti-cytokine therapy +/- steroids)

Prophy: prophylaxis, Infxn: infection, VZV, varicella virus, PJP: pneumocystis jiroveci pneumonia, IFI: invasive fungal infection

Jain T., et al. *Blood*. 2023; 141(2): 2460-68, Haidar G, et al. *Curr Opin Infect Dis*. 2020;33(6):449-457., Maus MV, et al. *J Immunother Cancer*. 2020 Dec;8(2):e001511., Shahid Z, et al. *Transplant and Cell Ther*. 2024;30 (10):955-959., Einarsdottir S, et al. *Blood Cancer Journal*. 2025; 15:114.

42



43

44



Specialty	Key Roles/Responsibilities in OP Setting
Nursing	• Provide day to day clinical monitoring and supportive care services • Recognize early CAR-T associated toxicities • Effectively communicate all aspects of CAR T-cell therapy to patients and families, and answer patient questions
APPs/ Providers	• Recognize the unique needs of patients receiving CAR T-cell therapy • Follow CRS/ICANS management algorithms, and administer interventions early • Communicate timely and efficiently with all CAR-T team members and consultative services
Case Managers	• Ensure support for high-cost medications • Assist with transitions of care from OP to IP when needed • Arrange supportive services including home health, PT/OT, etc.
Social workers	• Arrange lodging, transportation, and reimbursement assistance • Provide emotional support to patients and caregivers

45


Clinical Pharmacists: The Swiss Army Toolkit of OP CAR-T
Educator
Clinical Operations
Education to patients & caregivers on medication management and LD Chem
Provide education to staff members onboarding to service
Create LD chemo and cellular therapy electronic orders
Develop and review guidelines and SOP's
Verify and process LD chemo, supportive care meds
Labeling of CAR-T Product
Collaborate with team on management of toxicities
Clinical Services

46


Clinical and Operational Considerations
Patient
Limited comorbidities, PS >90, ECOG 0-1
Reliable caregiver
Transportation to and from center
Product/ disease burden
Stable disease without concern for severe CRS/NT
Predictability of toxicity timeline
Institutional
OP bed/chair availability
Access to 24/7 on-call care team for in-person or telemed evaluation
Multidisciplinary trained staff
Protocols/ SOPs
Dedicated cellular therapy coordinators /logistics team
Seamless transition of care from OP to IP setting

47


Various CAR-T Program Structures
HCT Program integrates all CAR-T services
HCT Program
HCT Pharmacists
HCT Nurses
HCT Ancillary Staff
HCT Providers
HCT and CAR-T Patients
Independent programs share initial services while staffing completed by respective service lines
CAR-T Program
HCT Program
HCT and CAR-T Nursing/Administrative Resources
HCT-enabled Multidisciplinary Team
CAR-T-enabled Multidisciplinary Team
CAR-T Patients allocated to HCT or CAR-T units (pre-set criteria)
CAR-T services provided by disease-specific unit with administrative and regulatory oversight by immunotherapy umbrella
HCT Program
Leukemia Program
Lymphoma Program
Myeloma Program
HCT Multidisciplinary Team
Hem/Onc Multidisciplinary Team
CAR-T Patients
Immunotherapy Institute
Heme/Onc: hematology/oncology
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

48


QUESTION ARS #3
2025 NCODA INTERNATIONAL FALL SUMMIT
Which of the following components is MOST critical to ensuring patient safety in an outpatient CAR-T program?
a. Clearly defined roles for each member of the multidisciplinary team
b. Standardized workflow for patient monitoring and escalation
c. Established protocols for managing cytokine release syndrome and neurotoxicity
d. All of the above
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

49


Best Practices for Institutional Operational Considerations
Regular Meetings
• Include clinical and ancillary members
• Cost/benefit review
• Workflow re-eval
Education of Support Service
• Emergency Department
• Urgent Care
• ICU
Development of SOP's and Workflows
• Patient selection
• Monitoring frequency
• Admission procedure
• Toxicity Management
Staff Education
• Clinical Standards
• Grand rounds
• Lecture series
• Onboarding boot camp for new hires
Quality Control/Metrics
• EMR/SOP variances
• Safety/efficacy Analysis
• Drug-use evaluations
• CIBMTR Reporting
• FACT compliance
Eval: evaluation, ICU: intensive care unit, FACT: Foundation for the Accreditation of Cellular Therapy
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

50


Multidisciplinary Standard Operating Procedures and Guideline Development
Devise comprehensive procedures + product-specific guidelines for OP
Leverage shared digital platforms for easy access to latest protocol
Complete detailed education for all staff on recognition of CAR-T toxicities and AE management
Review procedures of care escalation
Create process to recognize and intervene with prophy measures
Provide refresher training (new hires and cross covering staff)
Attend multidisciplinary meetings and educational sessions to assist with knowledge gaps and skills
Tumor boards
SOP development
Lecture series/ Conferences
Participate in QI initiatives
Continually optimize protocols in response to quarterly (or event-driven) protocol-review meetings with key stakeholders
Establish a formal document-control system
QI : quality improvement

51


Moffitt Cancer Center CAR-T Structure
Designated 8 bed outpatient infusion center for CAR-T plus 24 bed/chairs in BMT infusion clinic (shared with CAR-T) – Open everyday (~7AM-7PM)
Attending CAR-T Provider On Call
2 Nocturnist APPs (shared BMT/CAR-T)
Monitored Triage Line 24/7
Designated 2-3 APPs for OP CAR-T Management
Designated OP CAR-T Clinical Pharmacist
CAR-T clinics (Mon-Fri)
Direct admit process
Cell Therapy Facility (1-2) – available everyday
Patient/ caregiver monitoring kits
18 dedicated CAR-T RNs
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

52


Day in the Life of an Example OP CAR-T Service Line
Education by provider, nurse coordinator and/pharmacist
Clearance by social work, financial and/or consult services (ID, neuro, cards)
Pre-LD: Completion of VOT's +/-bridging
Baseline labs, imaging and treatment course review, line placement
Review of home medications
Prescribing of CAR-T related supportive care medications
Day -6: Clearance day completed by provider, APP and clinical pharmacist
Daily labs +/- APP visit
Clinical pharmacist to review ongoing LD toxicity
Day -5 through -3: Lymphodepleting chemotherapy
Collaboration between RN, cell therapy and clinical pharmacist for release of pre-medications and product labeling
Clearance by provider
If needed: initiation of prophylactic measures (dex, anakinra, other)
Day 0: Cell infusion
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

53


Coordination of Care for OP Monitoring: Standardized but Individualized
Create designated follow-up protocols for frequency of visits conducted by RN, APP +/- Provider in OP setting
On clearance day [D-6] and cell infusion [D0] (Provider and Clinical Pharmacist Required)
Structured expectations for daily OP monitoring (labs/VS at minimum)
Nursing assessment (Q4hr VS with ICE assessments during acute window)
Reinforcing responsibilities of care to patient/caregiver
Visit by APP +/- Provider
Frequency/duration based off CRS/ICANS timeframe
Designate number of daily visits (~7-14 days) for appropriate chair/bed scheduling
e.g. cilta-cel: daily monitoring D0 through D+10 vs. obe-cel or brexu-cel for ALL patient: D0 through D+14
Early transition discharges to OP setting
Email communication to key members (RN, APP leadership or designee) to accept candidate
Ensure OP capacity, staffing and medical suitability
VS: vital signs
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

54

Institution Infrastructure: Triaging and Admissions

Given approximately 30-50% of all OP treated patients may need an admission for CAR-associated toxicities and/or infection complications

- **Ensure adequate staffing for continuity of care**
  - ✓ Dedicated triage line to report after-hours medical issues
  - ✓ Dedicated/knowledge providers on call 24/7
    - ✓ Fellows, residents, hospitalists, APP's
- **Hospital bed access for escalation of care**
  - ✓ Direct admit from OP
  - ✓ Transfer from ED or Urgent Care



ED: emergency department

McGann M, et al. *Transplant Cell Ther.* 2022;28(9):583-589. Gatwood K, et al. *Clin Hematol Int.* 2024;6(2):1-20.

55

Patient and Caregiver Education Enhances Safety and Boosts Adherence to Clinical Protocols

- **Step 1:** Effective communication and understanding of caregiver responsibility for close patient monitoring
  - ✓ Need for 24-hour care and proximity to center for at least 2 weeks after treatment
  - ✓ Have a plan to ensure there are no gaps in caregiver availability
- **Step 2:** Patients/caregivers educated about the common AEs of CAR-T and when to seek care or treatment
  - ✓ Both trained in use of thermometer/blood pressure cuff
  - ✓ Provide checklists, wallet cards, etc. in case of transfer from outside facility

What to do in the event of an adverse event

Taylor L, et al. *Clin J Oncol Nurs.* 2019;23(2):20-26. Akins M, et al. *Future Oncol.* 2025;21(10):1137-1144.. Hansen DKD, et al. *Front Immunol.* 2024. Feb 21–24;15:1402452.

56

New Changes to REMS Mandate for CAR-T Products: **Reducing Barriers to Access and Regulatory Burden**

Pros	Cons	Potential Solutions
Removes requirement to maintain **special certification** and on-site, **immediate access to Toci**	Shifts responsibility for CRS/ICANS management onto institution's standard protocols (variable practices)	• Development of SOP's based upon current best practice GL • Robust toxicity surveillance and rapid-response infrastructure
Streamlines product labeling: safety information through BBW/med guides vs. separate REMS program	Without REMS-driven central oversight, data on rare or late toxicities may decline	• Standardize documentation & feedback to improve/support data capture • Ongoing QI metrics

BBW: black box warning, GL: guidelines

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies. Accessed August 18, 2025. from: https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor-. Abid MB, et al. *Transplant Cell Ther.* 2025;S2666-6367(25)01326-0.

57

New Changes to REMS Mandate for CAR-T Products: **Reducing Barriers to Access and Regulatory Burden**

Pros	Cons	Potential Solutions
Reduces administrative burden and $, potential increase in community referrals and **improvement in access**	Complacency over time, with less frequent refresher training on CAR-T toxicities and mitigation strategies	• Use ongoing educational sessions to highlight recognition of CRS and ICANS grading, symptoms and intervention
Shortens patient monitoring windows in updated labels • Driving restrictions 8→ 2 weeks • Proximity requirement 4→ 2 weeks	Removes a formal safety "check" that previously ensured meeting uniform standards	• Implement routine virtual check-ins from day 0–14 if not seen in person

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies. Accessed August 16, 2025. from https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor ; Abid MB, et al. *Transplant Cell Ther.* 2025;52666-6367(25)01328-0.

58

Summary: One Step Closer in De-centralizing Access to CAR-T

- OP CAR-T broadens care access, eases burden, and boosts satisfaction
- Enhanced toxicity detection, risk assessment, and early management makes OP delivery feasible
- Eligibility for OP administration hinges on patient and product safety criteria so choose wisely
- Successful implementation requires several components including knowledgeable personnel and clinical space
- Elimination of the REMS requirement is a shift in easing patient/caregiver burden, reducing delivery costs and enhances access equity

59

QUESTION & ANSWER

2025 NCODA INTERNATIONAL FALL SUMMIT

Reimagining CAR-T: The Outpatient Evolution

Rebecca Gonzalez, PharmD, BCOP, FASTCT

Blood and Marrow Transplant/Cellular Immunotherapy Clinical Specialist

Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

60


CE CODE
2025 NCODA INTERNATIONAL
FALL SUMMIT
Reimagining CAR-T:
The Outpatient Evolution
Championing Medically Integrated Oncology: CELEBRATING A DECADE OF IMPACT

61



62



63